Case Report: Ivermectin and Albendazole Plasma Concentrations in a Patient with Disseminated Strongyloidiasis on Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.

Abstract	Disseminated strongyloidiasis is often fatal, despite treatment with oral albendazole and parenteral ivermectin (IVM). Here, we report elevated plasma IVM and albendazole sulfoxide concentrations in the context of extracorporeal membrane oxygenation and continuous renal replacement therapy in a patient with disseminated strongyloidiasis treated with subcutaneous IVM and nasogastric albenzadole. Despite elevated drug plasma concentrations, live filariform larvae were detected in endotracheal aspirates after 2 weeks of treatment.
Authors	Carl Boodman, Yashpal S Chhonker, Daryl J Murry, Allison Mah, Jennifer Grant, Theodore Steiner, Michael Libman, Cesilia Nishi, Marthe Charles
Journal	The American journal of tropical medicine and hygiene (Am J Trop Med Hyg) Vol. 99 Issue 5 Pg. 1194-1197 (11 2018) ISSN: 1476-1645 [Electronic] United States
PMID	30226142 (Publication Type: Case Reports, Journal Article)
Chemical References	Anthelmintics Ivermectin Albendazole
Topics	Albendazole (blood, therapeutic use) Animals Anthelmintics (blood, therapeutic use) Extracorporeal Membrane Oxygenation Humans Ivermectin (blood, therapeutic use) Larva (drug effects) Male Middle Aged Renal Dialysis Strongyloides stercoralis (drug effects, isolation & purification) Strongyloidiasis (blood, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!